Találati lista | Tudóstér

001-es BibID:	BIBFORM103399
035-os BibID:	(Scopus)85149171419 (WoS)000952863200010
Első szerző:	Béldi Tibor (orvos)
Cím:	The effect of COVID-19 pandemic on idiopathic inflammatory myositis patients : a single centre experience / Béldi Tibor, Vincze Anett, Miltényi-Szabó Balázs, Varga Zsófia, Szabó Katalin, Griger Zoltán, Nagy-Vincze Melinda
Dátum:	2023
ISSN:	0392-856X 1593-098X
Megjegyzések:	Objectives: Pandemic caused by coronavirus disease (COVID-19) determines the life of clinicians and patients since 2 years. We have a lot of information about disease course, treatment and protection against virus, but less on the prognosis of infection in patients with idiopathic inflammatory myopathies (IIM). Also few data are available on triggered humoral response and side effects after vaccination. Methods: Our goal was to assess by a retrospective cross-sectional study the above data in our cohort (176 IIM patients) by identifying COVID-19 positive patients and follow disease course. Incidence and complications of vaccination were determined by questionnaires. 101 patients volunteered for complex blood test. Results: By June 1st, 2021 significantly higher incidence of COVID 19 infections (34.7%) were identified comparing to the national prevalence (8.2%). A third of these infections occurred asymptomatically or mild. Patients requiring hospitalisation had a significantly longer disease duration and a higher incidence of anti-Jo-1 antibody. All patients infected by COVID-19 became seropositive regardless the immunosuppressive therapy or symptoms severity. 54.3% of the patients received anti-COVID-19 vaccine. 72.3% of patients became seropositive after vaccination. Higher antibody titer against spike protein was detected after Pfizer-BioNTech vaccination compared to others. Patients receiving steroid therapy had decreased post-vaccination antibody response compared to those without steroid treatment. No major post-vaccination infection was observed. Conclusions: Based on our results, myositis may be associated with an increased risk of COVID-19 infection. Independent risk factor for hospitalisation are longer disease duration and anti-Jo1 positivity. Anti-SARS-CoV2 vaccines seem safe and tolerable and strongly recommended for that population.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk myositis interstitial lung disease COVID infection vaccination
Megjelenés:	Clinical And Experimental Rheumatology. - 41 : 2 (2023), p. 254-260. -
További szerzők:	Vincze Anett (1993-) (orvos) Miltényi-Szabó Balázs (1996-) (orvostanhallgató) Varga Zsófia (1992-) (molekuláris biológus) Szabó Katalin (1991-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM128093
035-os BibID:	(scopus)86000149599
Első szerző:	Bishnoi, Anuradha
Cím:	The Myositis Clinical Trials Consortium : an international collaborative initiative to promote clinical trials in adult and juvenile myositis / Bishnoi Anuradha, Tang Iris Yan Ki, Yoshida Akira, Pais Faye M., Usman Sabeena Y., Dominguez Solciris A., Kavadichanda Chengappa G., Rivero-Gallegos Daphne, Dourado Eduardo, Conticini Edoardo, Bozán Francisca, Tulluru Gayathri, Lilleker James B., Sreerama Reddy Kaushik, Landon-Cardinal Océane, Smaili Rachid, Keret Shiri, Khoo Thomas, Lan Ting-Yuan, Leclair Valérie, Oddis Chester V., Vencovsky Jirí, Kuwana Masataka, Gandiga Prateek C., Aggarwal Rohit, Myositis Clinical Trials Consortium investigators
Dátum:	2025
ISSN:	0392-856X 1593-098X
Megjegyzések:	Idiopathic inflammatory myopathies (IIM), or myositis, are a heterogeneous group of systemic autoimmune disorders that are associated with significant morbidity and mortality. Conducting high-quality clinical trials in IIM is challenging due to the rare and variable presentations of disease. To address this challenge, the Myositis Clinical Trials Consortium (MCTC) was formed. MCTC is a collaborative international alliance dedicated to facilitating, promoting, coordinating and conducting clinical trials and related research in IIM. This partnership works to advance the discovery of effective evidence-based treatments for IIM by integrating a diverse group of clinical investigators, research professionals, medical centres, patient groups, and industry partners. The Steering Committee, Core Group, and Paediatric Subcommittee of MCTC are comprised of myositis experts and junior investigators from around the world, representing a diversity of genders, geographies, and subspecialties. MCTC works alongside other current myositis organisations to complement existing work by concentrating on the operationalisation of clinical trials. Our pilot Myositis Investigators' Information Survey gathered responses from 173 myositis investigators globally and found considerable variability in proficiency with outcome measures, geographic disparities in patient recruitment, and a significant disconnect between investigators' routine myositis patient load and clinical trial enrolment. MCTC will meet the need to support and diversify myositis clinical trials by facilitating trial planning, feasibility assessments, site selection, and the training and mentoring of junior investigators/centres to establish their readiness for clinical trial participation. Through experienced leadership, strategic collaborations, and interdisciplinary discussions, MCTC will establish standards for IIM clinical trial design, protocols, and outcome measures in myositis.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk myositis rare diseases clinical trials outcome assessment organisation and administration
Megjelenés:	Clinical And Experimental Rheumatology. - 43 : 2 (2025), p. 202-210. -
További szerzők:	Tang, Iris Yan Ki Yoshida, Akira Pais, Faye M. Usman, Sabeena Y. Dominguez, Solciris A. Kavadichanda, Chengappa G. Rivero-Gallegos, Daphne Dourado, Eduardo Conticini, Edoardo Bozán, Francisca Tulluru, Gayathri Lilleker, James B. Sreerama Reddy, Kaushik Landon-Cardinal, Océane Smaili, Rachid Keret, Shiri Khoo, Thomas Lan, Ting-Yuan Leclair, Valérie Oddis, Chester V. Vencovsky, Jiri Kuwana, Masataka Gandiga, Prateek C. Aggarwal, Rohit Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Myositis Clinical Trials Consortium investigators
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: